Related Experiment Video

Updated: Mar 22, 2026

A Method for Measuring RNA N6-methyladenosine Modifications in Cells and Tissues
08:56

A Method for Measuring RNA N6-methyladenosine Modifications in Cells and Tissues

Published on: December 5, 2016

11.4K

Roles and clinical implications of N6-methyladenosine in digestive system tumors

Shixin Luo1, Lusheng Liu2, Min Sun3

  • 1Graduate School, Heilongjiang University of Traditional Chinese Medicine, Heilongjiang 150040, China.

Mutation Research. Reviews in Mutation Research
|March 20, 2026
PubMed

Insights

N6-methyladenosine (m6A) RNA modification is crucial in digestive cancers. Targeting m6A regulators offers potential for new biomarkers and therapies for these challenging tumors.

Area of Science:

  • Oncology
  • Epigenetics
  • Molecular Biology

Background:

  • Digestive system cancers (gastric, colorectal, esophageal, hepatocellular, pancreatic, gallbladder) pose a significant global health challenge due to high incidence, malignancy, late diagnosis, and poor prognosis.
  • There is an urgent need for novel diagnostic biomarkers and innovative therapeutic strategies for these malignancies.

Purpose of the Study:

  • To review the critical role of N6-methyladenosine (m6A) RNA modification and its regulators in the pathobiology of digestive system tumors.
  • To explore the potential of m6A regulators as diagnostic biomarkers and therapeutic targets for digestive cancers.

Main Methods:

  • Literature review focusing on the "author", "eraser", and "reader" proteins involved in m6A RNA modification.
  • Analysis of the impact of m6A dysregulation on tumor development and treatment outcomes in digestive cancers.

Main Results:

  • N6-methyladenosine (m6A) RNA modification is the most prevalent epigenetic mark on eukaryotic mRNAs and plays a multifaceted regulatory role in digestive cancer pathobiology.
  • Dysregulation of m6A regulators is closely linked to tumor development, progression, and patient treatment outcomes in digestive system malignancies.

Conclusions:

  • m6A RNA modification critically influences the pathobiology and therapeutic responses in digestive cancers.
  • m6A regulators are promising candidates for future diagnostic biomarkers and therapeutic targets, potentially guiding future diagnosis, treatment, and prevention strategies for digestive system tumors.
Keywords:
BiomarkersClinical demandDigestive system tumorsEpigenetic modificationRNA modification

More Related Videos

MeRIP-qPCR Assay for Detecting m6A Modification Levels of Specific RNA in Osteosarcoma Cells05:16

MeRIP-qPCR Assay for Detecting m6A Modification Levels of Specific RNA in Osteosarcoma Cells

Published on: December 30, 2025

321
Characterizing RNA Modifications in Single Neurons Using Mass Spectrometry08:45

Characterizing RNA Modifications in Single Neurons Using Mass Spectrometry

Published on: April 21, 2022

2.8K

Related Concept Videos

Biosynthesis of Nucleic Acids01:28

Biosynthesis of Nucleic Acids

Nucleic acid biosynthesis is a fundamental biochemical process that produces the purine and pyrimidine nucleotides essential for DNA and RNA synthesis. This pathway maintains a balanced nucleotide pool, preventing imbalances that could jeopardize genetic integrity and cellular function. Given the crucial role of nucleotides, their synthesis is tightly regulated to ensure proper cellular homeostasis.Purine BiosynthesisThe biosynthesis of purine nucleotides begins with ribose-5-phosphate, a...
1.5K
RNA Editing02:23

RNA Editing

RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
10.1K
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
58
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.2K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.6K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
65